Heterologous Prime Boost Regimes with N-terminal Peptides of Ag85B Induces Better Protection than Ag85B and BCG in Murine Model of Tuberculosis

Abebe F, Bjune G (2009) The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol 157:235–243 Agger E, Andersen P (2002) Novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 21:7–14 Allen PM, Strydom DJ, Unanue ER (1984) Processing of lysozyme by macrophages: identification of the determinant recognized by two T-cell hybridomas. Proc Natl Acad Sci USA 81:2489–2493 Andersen P, Doherty TM (2005) The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3:656–662 Barreto M, Pereira S, Ferreira A (2006) BCG vaccine: efficacy and indication for vaccination and revaccination. J Pediatr (Rio J) 82:45–54 Bosio C, Gardner D, Elkins K (2000) Infection of B cell-deficient mice with CDC a clinical isolate of Mycobacterium tuberculosis. J Immunol 164:6417–6425 Brandt L, Feino Cunha J, Weinreich Olsen A et al (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70:672–678 Chodisetti SB, Rai PK, Gowthaman U et al (2012) Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis. BMC Immunol 13:13 Demangel C, Garnier T, Rosenkrands I, Cole ST (2005) Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 73:2190–2196 Gowthaman U, Rai P, Khan N et al (2012) Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions. Trends Mol Med 18:607–614 Husain AA, Kashyap RS, Kalorey DR, Warke SR et al (2011) Effect of repeat dose of BCG vaccine on humoral response in mice model. Indian J Exp Biol 49:7–10 Husain AA, Warke SR, Kalorey DR et al (2015a) Comparative evaluation of booster efficacies of BCG, Ag85B, and Ag85B peptides based vaccines to boost BCG induced immunity in BALB/c mice: a pilot study. Clin Exp Vaccine Res 4:83–87 Husain AA, Daginawala HF, Warke SR et al (2015b) Kashyap RS. Investigation of immune biomarkers using subcutaneous model of M. tuberculosis infection in BALB/c mice: a preliminary report. Immune Netw 15:83–90 Kashyap RS, Husain AA, Morey SH et al (2010) Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model. J Immune Based Ther Vaccines 8:3 Kashyap RS, Nayak AR, Husain AA et al (2013a) Tuberculosis in India: the continuing challenge. Curr Sci 105:597–606 Kashyap RS, Shekhawat SD, Nayak AR et al (2013b) Diagnosis of tuberculosis infection based on synthetic peptides from Mycobacterium tuberculosis antigen 85 complex. Clin Neurol Neurosurg 115:678–683 Kashyap RS, Nayak AR, Gaikwad S, et al (2013c) Biomarkers in pulmonary and extra pulmonary tuberculosis. In: Proceedings of the international conference on advances in developing affordable invitro molecular diagnostics 73–86 Kolibab K, Yang A, Parra M et al (2014) Time to detection of Mycobacterium tuberculosis using the MGIT 320 system correlates with colony counting in preclinical testing of new vaccines. Clin Vaccine Immunol 21:453–455 Luby SP, Brooks WA, Zaman K et al (2008) Infectious diseases and vaccine sciences: strategic directions. J Health Popul Nutr 26:295–310 Martin C (2005) The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG. Eur Respir J 26:162–167 McShane H, Hill A (2005) Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7:962–967 Mollenkopf HJ, Kursar M, Kaufmann SH (2004) Immune response to post primary tuberculosis in mice: mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Guerin induce equal protection. J Infect Dis 190:588–597 Monika AP, Sergiusz M, Elzbieta K et al (2011) Proteomics for development of vaccine. Proteomics 74:2596 Mustafa AS, Shaban FA, Abal AT et al (2000) Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines. Infect Immun 68:3933–3940 Olsen AW, Hansen PR, Holm A et al (2000) Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30:1724–1732 Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6:404–414 Senova L, Harbacheuski R, Moreira AL et al (2006) Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 74:2392–2401 Sugawaraa I, Udagawaa T, Taniyamab T (2006) Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. J tube 87:94–101 Tameris MD, Hatherill M, Landry BS et al (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021–1028 Valle MT, Megiovanni AM, Merlo A et al (2001) Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85. Clin Exp Immunol 123:226–232 Zugel U, Sponaas A, Neckermann J et al (2001) gp96-Peptide vaccination of mice against intracellular bacteria. Infect Immun 69:4164–4167 Zuñiga J, Torres G, Santos M et al (2012) Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012:193923